Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NEMA Code Clarifies Ethics Of R&D Grants, Drops “Entertainment” Entirely

This article was originally published in The Gray Sheet

Executive Summary

The National Electrical Manufacturers Association's new code of ethics endorses strict parameters for device company allocation of research funds to healthcare providers

You may also be interested in...



MDMA to establish ethics code

Medical Device Manufacturers Association is developing a code-of-conduct similar to those for PhRMA and AdvaMed, MDMA Chairman Chris Chavez, CEO of Advanced Neuromodulation Systems, reports at a Morgan Stanley healthcare conference in Miami. The National Electrical Manufacturers Association's code of ethics was approved at the end of 2004; AdvaMed's has been in effect for two years (1"The Gray Sheet" Dec. 6, 2004, p. 12)...

MDMA to establish ethics code

Medical Device Manufacturers Association is developing a code-of-conduct similar to those for PhRMA and AdvaMed, MDMA Chairman Chris Chavez, CEO of Advanced Neuromodulation Systems, reports at a Morgan Stanley healthcare conference in Miami. The National Electrical Manufacturers Association's code of ethics was approved at the end of 2004; AdvaMed's has been in effect for two years (1"The Gray Sheet" Dec. 6, 2004, p. 12)...

Golf Ball Gifts, Spouse Travel Funds Prohibited By AdvaMed Ethics Code

AdvaMed's voluntary code of ethics on interactions with healthcare professionals will become effective for manufacturers Sept. 1, following a "grace period" to allow for changes to the HHS Office of Inspector General's pharmaceutical compliance draft guidance

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel